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treatment patterns and drug treatment costs in such patients. METHODS: Retro-
spective analysis of pooled US health insurance claims data for commercially in-
sured (Pharmetrics/I3/Thomson) and Thomson Medicaid patients, 2007–2009.
RESULTS:Data from 14,002 treatment-naïve patientswere collected. 6,801 patients
(49%) started on an NNRTI (of which 99.8% on efavirenz, mainly as part of a fixed-
dose combination), 5,966 (43%) on a PI and 1,235 (9%) on an II or another third agent.
As expected due to the teratogenic potential of efavirenz, substantially fewer
women aged40 years started NNRTI treatment (32.5% vs 60% starting a PI). Of all
patients who started on efavirenz, 66% remained on this initial treatment at 1 year.
Of patients who switched to another regimen after discontinuing efavirenz, 85%
changed to a PI-based regimen. At the start of efavirenz treatment,mean daily drug
cost (including 2 NRTIs) was 46 USD. For patients who switched subsequently to a
PI-based regimen, mean daily drug cost rose by 51% to 70 USD. Corresponding
values from the individual databases were consistent. CONCLUSIONS:Within one
year after initiation of therapy,many patients discontinue efavirenz.When chang-
ing to another regimen, themajority switch to a PI, with an associated rise in costs.
The study highlights opportunities in the current HIV treatment-naïvemarket and
the need for new third agents which are as effective but better tolerated than
efavirenz, and may be used in women of childbearing potential. Such agents may
alleviate the need to start with and/or delay the switch to more expensive treat-
ments, potentially reducing HIV treatment costs.
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OBJECTIVES: Vaccinating birth mothers with influenza vaccine in the immediate
postpartum period can protect both the vaccine recipients and their young infants
who are ineligible for any influenza vaccine. The study objective was to estimate
the potential economic benefit associated with this intervention. METHODS: A
decision analysis model was constructed to determine the probabilities, costs and
potential cost-benefit of a postpartum influenza vaccination strategy using a soci-
etal perspective. A hypothetical cohort of 4 million healthy birth mothers in the
United States was included into a decision tree model assuming an influenza sea-
son beginning September 1 and ending April 30. Probabilities and costs used in this
study were derived from our review of published literature, unpublished data re-
ported from Centers for Disease Control and Prevention (CDC), and recent pub-
lished clinical trial data. All direct and indirect cost estimates were inflated to year
2010 US dollars and discounted at a 3% annual discount rate. RESULTS: Under the
base-case assumptions, the average costs per vaccinated mother and per unvacci-
nated mother were estimated at $328.45 and $341.02, respectively. Our model sug-
gests an expectednet societal benefit of $12.57 per post-partumvaccinatedmother,
compared to no vaccination. The overall societal savings in this cohort ranged from
$20,112,186 to $45,252,420, depending on the vaccination coverage rate. Annual
attack rate in birth mothers and influenza vaccine efficacy also exhibited substan-
tial impact on the model from one-way and two-way sensitivity analyses.
CONCLUSIONS: Widespread adherence to a postpartum influenza vaccine usage
strategy is likely to show positive net societal benefits in the United States, if the
annual attack rate among birth mothers exceeds 2.8%, if the influenza vaccine
efficacy reaches 47%, or if vaccine acquisition and administration cost per dose is
less than $32.78.
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OBJECTIVES: Estimating the financial benefit or cost of using anti-retroviral med-
ications (ARVs) for treating HIV in Uganda in light of poor concordance, risk of
treatment resistant strains developing, patients living longer and the potentially
increased risk of spreading the virus. METHODS: We performed a cost-benefit
study to analyze the effects, in monetary terms, of ARVs in Uganda, from the
societal perspective. Data were obtained from administering institutions such as
the ministry of health, identified non-governmental organizations such as The
Aids Support Organization (TASO), Mildmay International, and research centers
plus published literature. Human capital approach was used to estimate costs.
Monetary estimateswere available in Uganda shillings and their dollar equivalents
were computed. The study included programs specifically funded by donor funds
and/or the Ugandan government. RESULTS: The estimated net benefit from ARVs
for a year was estimated at $8,250 per patient. Benefits were in the form of im-
proved productivity resulting from prolonged life overall with minimal counter-
effects of developing treatment resistant strains and increased risk of spreading
the virus. One-way sensitivity analysis showed the net benefit to vary from $1,656
to $13,871. CONCLUSIONS: Using ARVs to treat HIV in Uganda is cost beneficial for
the Ugandan society.
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OBJECTIVES: Pneumococcus was responsible formore than 50% of the preventable
deaths in infants under 5 years of age according to the Pan American Health Orga-
nization before the introduction of conjugate vaccines. The objective of this anal-
ysis is to evaluate the cost effectiveness of vaccinating the Colombian population
younger than 2 years of age with 13-valent vaccine (PCV 13) in comparison to the
10-valent or PHiD-CV vaccine (PCV 10) both in same schedule.METHODS: In order
to estimate the costs and the impact of the pneumococcal disease, aMarkovmodel
simulating vaccination and outcomes of 10 annual birth cohortswas adapted to the
Colombian conditions from the Health System perspective. The probabilities and
the costs were extracted from a literature review and tariff manuals applicable for
Colombia for January 2011, with costs presented in US$. The results in health are
expressed as number of cases of diseases and deaths prevented, as well as in terms
of life years (LYs) and QALYs saved. Probabilistic sensitivity analyses were done.
RESULTS: Over a 10 year period, vaccinating with PCV13 prevents 8,191 cases of
invasive pneumococcal disease, 58,587 hospitalized pneumonia, 5,583 non com-
plicated pneumonia and 2,927 deaths, saving 70,640 LY’s and 63,697 QALY’s
compared to PCV10. PCV10 prevents 49,354 additional cases of acute otitis me-
dia versus PCV13. The total costs including vaccination costs and medical costs
are US$ 89,608,061 less for PCV13 compared to PCV10 (US$ 2,365,043,131 vs. US$
2,454,651,191). The model shows robustness in the sensibility analysis.
CONCLUSIONS: The analysis suggests that vaccinating infants with PCV13 in Co-
lombia is a cost-saving alternative in comparison with PHiD-CV. The results in
economic and disease burden are substantial and they support the decision mak-
ing in favor of PCV13 for its high impact in public health.
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OBJECTIVES: Hepatitis B virus (HBV) causes 0.2% of world deaths, especially in
developing countries. This does not include deaths of hepatocellular carcinoma
(HCC), and hepatic cirrhosis (HC) caused by HBV. To diminish the burden of HBV
chronic and acute infection, in an unvaccinated cohort, we proposed a cost-effec-
tiveness analysis to assess the impact of the introduction of HBV vaccine in Co-
lombian adolescents.METHODS: A Markov model was made for two cohorts (vac-
cinated and unvaccinated) of people between 15 and 20 years old, who were be
followed for 30 years. Vaccination was assumed 97% effective in a three dose
scheme, and coverage of 70%. Costs were obtained from a database of Colombian
private health insurers. A model to estimate natural history of HBV infection was
used, along with data from literature reviews. All costs were 2009 US dollars. Vac-
cine administration cost plus vaccine price were assumed as US$7. A 3% discount
rate was applied to cost and outcomes. A sensitivity analysis was made to assess
the uncertainty in the assumptions.RESULTS:Deaths fromHBV infectionwould be
709 in the cohort without vaccination, and 228 in the cohort with vaccination.
Life-years gained (LYG) from vaccination with 70% coverage would be 12,266. Total
cost in not vaccinated is US$27,840,220; in vaccinated is US$8,936,710. Incremental-
Cost-Effectiveness Ratio (ICER) per LYG would be 665 US$/LYG. ICER per avoided
death would be 16,957 US$/avoided death. CONCLUSIONS: HBV vaccine is highly
cost-effective according toWorld Health Organization criteria (less than per-capita
gross domestic product). This is the first study that assessed the adolescent vacci-
nation with HBV in Latin America. The investigators strongly recommend the im-
plementation of this intervention to impact the burden of disease HBV-associated
in Colombia.
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OBJECTIVES: In the last years in Mexico HIV/AIDS appears within the first seven
causes of mortality among the population between 15 and 64 years old (SINAIS).
Boosted PI combination therapy, in combination with other advances, has lowered
the mortality rate among HIV-infected patients almost to that of the uninfected
population. The 96-week CASTLE randomized trial demonstrated that, in HAART-
naïve patients, ATV/RTV was non-inferior to LPV/RTV for suppressing viral repli-
cation and caused lower rates of GI toxicity and lower increases in total cholesterol.
In this study we evaluated the cost-effectiveness of ATV/RTV versus LPV/RTV in
treatment-naïve HIV patients in Mexico, using results from the CASTLE study.
METHODS: A lifetime Markov micro simulation model was used to estimate the
cost per QALY for both therapies lifetime costs, clinical outcomes and cost-effec-
tiveness. Tenofovir-emtricitabinewas considered the backbone therapy. Amillion-
member cohort of HIV-infected, treatment-naïve adults progressed at 3-month
intervals through 8 health states. The model measures the cost per adverse event
averted of the ATV based regime, focusing in particular on GI and coronary heart
disease outcomes. The analysis was conducted from the Mexican Health care per-
spective. Outcomes were discounted at a 5% rate. Virologic suppression, health
state transition probabilities, cholesterol changes, and side effect rates were de-
rived from CASTLE. Costs and utilities were derived from literature and expert
opinion. RESULTS: Patients initiating ATVRTV regime had longer quality-ad-
justed survival than those initiating LPVRTV, (10.47 vs. 10.26 years) and lower
total costs ($95,579 vs. $103,891 USD) resulting in a more effective and less costly
treatment option (dominant alternative). Sensitivity analyses demonstrated that
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the model is robust to a wide range of parameter estimates. CONCLUSIONS: This
analysis suggests that the use of ATVRTV in the Mexican healthcare setting is a
preferred option when compared to LPVRTV for treatment of treatment-naïve
HIV patients.
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OBJECTIVES: To examine the incremental cost-effectiveness of palivizumab vs. no
prophylaxis among 3 groups of preterm infants in a Medicaid population. Infants
were6months of age at the start of the RSV season: 1)32 weeks gestational age
(wGA); 2) High-risk (HR) 32–35 wGA ( 2 risk factors) or 3) Low-risk (LR) 32–35 wGA
(1 risk factor). METHODS: We conducted a cost-utility analysis of palivizumab
from a societal perspective based on 5 monthly doses throughout the RSV season.
Medicaid-related inputs included the background rates of RSV disease, marginal
healthcare costs within the first two years of life between infants with RSV com-
pared to controls, and the estimated public payer dollars spent for palivizumab.
The base case included recurrent wheezing (RW), which was excluded during sen-
sitivity analysis.We report the incremental cost-effectiveness ratio (ICER), morbid-
ity, and mortality between the prophylaxed and non-prophylaxed groups.
RESULTS: Prophylaxis among 32 wGA infants was dominant, with and without
RW. For HR 32-35 wGA infants, the ICER was $3,791/QALY with RW and $26,290/
QALY without RW. For LR 32-35 wGA infants, the ICER was $22,690/QALY with RW
and $231,784/QALY without RW. Compared with infants without prophylaxis, in-
fants receiving prophylaxis were projected to have fewer RSV hospitalizations
(-4214 among 32 wGA, 4734 among HR 32-35 wGA, and 1289 among LR 32-35
wGA infants) among the estimated 119,500 premature births inMedicaid in the US.
Likewise, prophylaxis was estimated to reduce the number of deaths by 42 among
32 wGA, 74 among HR 32-35wGA and 20 among LR 32-35 wGA infants.
CONCLUSIONS: Palivizumab was shown to be highly cost-effective among infants
32 wGA and HR 32-35 wGA due to Medicaid’s lower cost structure for healthcare
items and services and higher rates of disease compared to private plans. The
study was sponsored by MedImmune, LLC.
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OBJECTIVES: To perform a cost-effectiveness analysis of the introduction of the
varicella vaccine in theNational Immunization Programof Colombia.METHODS:A
decision analysis model was built to follow two cohorts from birth. One cohort had
vaccination, and the other did not. The time horizon was 30 years. The perspective
was from the third payer. Amicro-costing assessment of varicella in Colombia was
undertaken. All costs were expressed in 2008 dollars of December 31. Incremental
cost-effectiveness ratio (ICER) was the main outcomemeasure. A discount rate for
health benefits and costs of 3%was used. A sensitivity analysis wasmade to assess
assumptions uncertainty. RESULTS: Vaccination would avoid 9,415,444 consulta-
tions, 17,576 hospitalizations, and 1,144 varicella deaths. Cost per Life-Year Gained
(LYG) was US$2,527/LYG. From the third payer perspective in Colombia, varicella
costs without vaccination would be US$88 millions, and with vaccination US$35
million. The sensitivity analysis shows that the vaccination strategy is not cost-
effective if vaccination cost per dose is higher than US$15.6. In the case of a booster
dose every ten years, the vaccinationwould not be cost-effective if vaccination cost
per dose is higher than US$9.8. CONCLUSIONS: Varicella vaccination is highly
cost-effective according toWorld Health Organization criteria (less than per capita
gross domestic product). The authors recommend, weighting the budget impact,
the implementation of the varicella vaccine in Colombia.
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OBJECTIVES: The recent increase of methicillin-resistant S. aureus (MRSA) as the
leading cause of bacteremia, and subsequent infective endocarditis, has led clini-
cians to resort to alternative treatments, rather than the traditional penicillin-
based treatment strategy. Such alternatives include daptomycin,whichhas proven
to be efficacious. An economic evaluation was performed to determine the most
cost-effective alternative between daptomycin and vancomycin for the treatment
of patients with MRSA bacteremia and infective endocarditis. METHODS: A cost-
effectiveness analysis was performed from an institutional perspective (Mexican
Institute of Social Security, IMSS). Vancomycin is currently the treatment of choice
for infective endocarditis within the treatment guidelines; daptomycin is regarded
as an alternative treatment. Effectiveness and safety data was taken from pub-
lished literature; effectiveness parameters included clinical and bacteriological
cure, and safety parameters included drug-related adverse events. Resource use
data was obtained from the institution; total direct costs of hospitalization and
treatment were considered. The source of the unit costs was the institution, cur-
rent for 2010. All costs are expressed in local currency (Mexican Pesos, MXP). The
time horizon was less than 1 year; no discount rate was used. A decision tree was
built with three possible outcomes considered: success or failure to treatment, and
death. A probabilistic sensitivity analysis was performed through a Monte Carlo
simulation with 100,000 iterations to confirm the robustness of the model.
RESULTS: The results show a cost/effectiveness ratio of $371,813.80 MXP for dap-
tomycin compared to $466,229.23MXP for vancomycin,making daptomycin amore
cost-effective alternative (dominant) for the treatment of bacteremia and infective
endocarditis. CONCLUSIONS: From an institutional perspective in Mexico, dapto-
mycin is a more cost-effective (dominant) alternative than vancomycin for the
treatment of bacteremia and infective endocarditis in patients with MRSA infec-
tion.
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OBJECTIVES: The loss of vaccine-induced immunity to pertussis over ten years
after administered increment the burden of pertussis-related disease. To diminish
the burden of pertussis-related disease on children under-5 years we propose a
cost-effectiveness analysis of the introduction of pertussis vaccine in Colombian
adolescents. METHODS: Two cohorts (with vaccinated and unvaccinated adoles-
cents) of childrenwere followed from birth to 5 years (both vaccinatedwith current
scheme: 2-4-6-18 months and 5 years with DTwP). A decision model was used to
estimate the burden of pertussis-related disease. The cost of pertussis was taken
from a previous study. A government perspective was used. Vaccine administra-
tion cost plus vaccine price were assumed between US$5-US$12 per dose. Adoles-
cent vaccination coveragewasassumed tobe 70%.Adeterministic sensitivity analysis
was performed. Costs were US dollars from 2008. RESULTS: Without adolescents
vaccination, the current scheme reduce 93% pertussis cases (from 102,196 to 6,912),
83% deaths (from 408 to 55), and 93% DALYs (18,189 to 1,233). With adolescent
vaccination, cases would reduce from 6,912 to 4,838, deaths from 408 to 39, and
DALYs from 1,233 to 860, in the current scenario. Total pertussis costs without
adolescent vaccination is US$737,186, andwith vaccination US$516,030. Incremen-
tal Cost-Effectiveness Ratiowith a vaccination coverage of 70%would go from4,188
(vaccination cost per dose: US$5) to 10,331 (vaccination cost per dose: US$12).
CONCLUSIONS: This is the first study in a developing country that assesses per-
tussis vaccination in adolescent. Pertussis adolescent vaccination was cost-effec-
tive in Colombia, according to World Health Organization criteria (less than three
times the per-capita Gross Domestic Product). The investigators recommend ado-
lescents pertussis vaccination in Colombia.
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OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in Bra-
zil for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital warts
in women age 9 to 26 years. We assessed the health and economic impact of the
quadrivalent (6,11,16,18) HPV vaccine from the healthcare system perspective in
Brazil.METHODS: A publishedmathematical model of the transmission dynamics
of HPV infection and disease was adapted for Brazil. Model inputs were used from
Brazil or the Latin/America region when available; otherwise, the default values in
the original model were used. Maintaining current cervical cancer screening prac-
tices in Brazil, we evaluated two strategies: routine vaccination of females by age 12
(S1), and S1 combined with a temporary (5 years) female catch-up program for age
12–24 years (S2). The vaccine coverage rates were 85% for the routine and 50% for
the catch-up vaccination programs. RESULTS: The most effective strategy was S2.
Comparing S2 to no vaccination, we estimated the cumulative percent reduction in
incident HPV 6/11/16/18-related genital warts-female, genital warts-male, cervical
intraepithelial neoplasia (CIN) grade 1, CIN 2/3, and cervical cancer cases would be
81%, 57%, 70%, 72%, and 59%, respectively over 100 years. The cost-effectiveness
ratios were Brazil Reals 1,203 (US$ 699) per quality-adjusted life years (QALY)
gained for S1 compared with no vaccination, and Brazil Reals 1,522 (US$ 885) per
QALY gained for S2 compared with S1. CONCLUSIONS: In Brazil, vaccination of
females age 12–24 years with a quadrivalent (6,11,16,18) HPV vaccine can reduce
the incidence of cervical cancer, CIN, and genital warts at a cost per QALY ratio
within the range typically regarded by the World Health Organization as cost-
effective.
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OBJECTIVES: The incidence of skin and soft tissue infections (SSTI) has augmented
recently in Mexico, mainly due to increases in vancomycin-resistant pathogens
and immunocompromised patients. New antibiotics, such as daptomycin, have
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